Pradaxa lawsuits mount

Boehringer Ingelheim is facing lawsuits in the United States over claims that dabigatran etexilate mesylate (Pradaxa) capsules, a blood-thinner used to reduce the risk of stroke and blood clots in people with atrial fibrillation not caused by a heart valve problem, causes severe and fatal bleeding. » Full article

Oxytrol goes OTC

Although the Oxytrol transdermal patch has been available as a prescription product since 2003, in January 2013 FDA approved Oxytrol for Women as an over-the-counter (OTC) product indicated for the treatment of overactive bladder in women ages 18 years and older. » Full article

Continuing Education

New CPE series: MTM Considerations for Adult Patients with CVD

Drug Topics kicks off a new CPE series, MTM Considerations for Adult Patients with Cardiovascular Disease, which will include 12 knowledge-based activities worth up to 24 credits. The goal of the first activity, “MTM essentials for cholesterol management,” will empower pharmacists to utilize current understanding of cholesterol management to improve patient care. To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.

Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net. This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

VIDEO: New hepatitis C drugs better and faster

Less than three years ago, the FDA approved two new breakthrough drugs for treating chronic hepatitis C (HCV)—Victrelis (boceprevir) and Incivek (telaprevir)—the first protease inhibitors approved for HCV. Although their introductions caught the attention of the marketplace, their successors are arriving quickly.
» Full article

• Long-term data reinforce safety profile of dabigatran etexilate mesylate

• FDA panel votes against making oxybutynin transdermal patch OTC

RESOURCES

Drug Watch

Latest Clinical News